ArticleEuropean journal of pediatrics2025
PEN-FAST in pediatrics: a reliable tool for penicillin allergy assessment?
Article in European journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Computational Approaches to Penicillin Allergy De-labelling: A Clinical Review.Clinical reviews in allergy & immunology · 2026Review
- Direct single dose mass delabelling of antibiotic allergy in pediatrics.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2026Article
- De-Labelling Penicillin Allergies in the Paediatric Emergency Department.Antibiotics (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Suspected penicillin allergy presents a significant challenge in the selection and management of antimicrobial therapy for patients. The PEN-FAST clinical decision score was developed and validated to identify individuals at low risk of penicillin allergy. This study aims to assess the applicability of the PEN-FAST scoring system in pediatric patients with a history of penicillin allergy who have undergone diagnostic testing for suspected reactions. Patients aged 6 to 18 years who presented with a history of penicillin allergy to the Pediatric Allergy and Immunology Department of Bilkent City Hospital between January 2017 and November 2024 were included in the study. Demographic, clinical and laboratory data of the patients were obtained from medical records. During the study period, 700 patients with suspected hypersensitivity reactions to penicillins were included. 55.3% were male; the median age at the time of the reaction was 6 years (IQR: 4-9.4). The most frequently implicated penicillin was amoxicillin-clavulanate (91%). Penicillin allergy was confirmed in 64 patients (9.1%). All 64 patients with positive diagnostic test results had a PEN-FAST score of 3 or higher. The performance of the PEN-FAST score ≥ 3 points demonstrated a sensitivity of 100% (95% CI, 0.94-1.00), a specificity of 45% (95% CI, 0.41-0.49), a positive predictive value (PPV) of 15% (%95 CI:0.12-0.19), and a negative predictive value (NPV) of 100% (95% CI, 0.98-1.00). The PEN-FAST score ≥ 3 points revealed a good discrimination in our cohort with AUC of 73% (95% CI, 0.68-0.77).
conclusionIn outpatient settings, PEN-FAST may facilitate the rapid identification of low-risk patients and aid in the planning of diagnostic testing. New validated point-of-care clinical tools are needed to identify low-risk penicillin allergies in children, and further validation of PEN-FAST is required in larger international cohorts. WHAT IS KNOWN: • Suspected penicillin allergy presents a significant challenge in the selection and management of antimicrobial therapy for patients. PEN-FAST is a diagnostic tool used to identify low-risk patients for penicillin allergy. WHAT IS NEW: • In our large pediatric cohort, we demonstrated that the PEN-FAST score could be a useful tool for identifying low-risk patients in an outpatient setting. New validated point-of-care clinical tools are needed to identify low-risk penicillin allergies in children, and further validation of PEN-FAST is required in larger international cohorts.
Indexed as
Identifiers
40601050What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.